Literature DB >> 23684623

Pharmacology, physiology, and mechanisms of incretin hormone action.

Jonathan E Campbell1, Daniel J Drucker2.   

Abstract

Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose concentrations, lipid metabolism, gut motility, appetite and body weight, and immune function, providing a scientific basis for utilizing incretin-based therapies in the treatment of type 2 diabetes. Activation of GLP-1 and GIP receptors also leads to nonglycemic effects in multiple tissues, through direct actions on tissues expressing incretin receptors and indirect mechanisms mediated through neuronal and endocrine pathways. Here we contrast the pharmacology and physiology of incretin hormones and review recent advances in mechanisms coupling incretin receptor signaling to pleiotropic metabolic actions in preclinical studies. We discuss whether mechanisms identified in preclinical studies have potential translational relevance for the treatment of human disease and highlight controversies and uncertainties in incretin biology that require resolution in future studies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23684623     DOI: 10.1016/j.cmet.2013.04.008

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  399 in total

1.  The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.

Authors:  Y Diz-Chaves; L Toba; J Fandiño; L C González-Matías; L M Garcia-Segura; F Mallo
Journal:  J Neuroinflammation       Date:  2018-12-05       Impact factor: 8.322

Review 2.  Type 2 diabetes mellitus and hypertension: an update.

Authors:  Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 3.  Mechanisms of weight loss and improved metabolism following bariatric surgery.

Authors:  Christopher M Mulla; Roeland J W Middelbeek; Mary-Elizabeth Patti
Journal:  Ann N Y Acad Sci       Date:  2017-09-03       Impact factor: 5.691

Review 4.  Paracrine signaling in islet function and survival.

Authors:  Sean M Hartig; Aaron R Cox
Journal:  J Mol Med (Berl)       Date:  2020-02-17       Impact factor: 4.599

5.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

Review 6.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

7.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

8.  Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.

Authors:  Matthew R Hayes; Elizabeth G Mietlicki-Baase; Scott E Kanoski; Bart C De Jonghe
Journal:  Annu Rev Nutr       Date:  2014-04-10       Impact factor: 11.848

9.  Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats.

Authors:  Lene Jessen; Eric P Smith; Yvonne Ulrich-Lai; James P Herman; Randy J Seeley; Darleen Sandoval; David D'Alessio
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

10.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

Authors:  Brian Finan; Bin Yang; Nickki Ottaway; David L Smiley; Tao Ma; Christoffer Clemmensen; Joe Chabenne; Lianshan Zhang; Kirk M Habegger; Katrin Fischer; Jonathan E Campbell; Darleen Sandoval; Randy J Seeley; Konrad Bleicher; Sabine Uhles; William Riboulet; Jürgen Funk; Cornelia Hertel; Sara Belli; Elena Sebokova; Karin Conde-Knape; Anish Konkar; Daniel J Drucker; Vasily Gelfanov; Paul T Pfluger; Timo D Müller; Diego Perez-Tilve; Richard D DiMarchi; Matthias H Tschöp
Journal:  Nat Med       Date:  2014-12-08       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.